Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03490344 · OUTCOME

Number of Participants With MRD Negativity by the Completion of 6 Months of Daratumumab Therapy

Short Course Daratumumab in Patients With Multiple Myeloma · Source last updated 2025-05-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
6 months

Groups in this outcome

Participants With Multiple Myeloma

Participants with MM with very good partial response (VGPR) or better after induction therapy with/without consolidative HDT/ASCT and MRD positive by bone marrow flow cytometry and MM participants who were previously MRD negative after induction and consolidation and recently (within last 3 months) turned MRD positive by bone marrow flow cytometry will be enrolled.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Participants With Multiple Myeloma10

Reported measurements

Source class 1

Conversion from MRD-negativity to MRD-positivity

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Participants With Multiple Myeloma6Not reportedNot reportedNot reportedNot reported

Persistent MRD-positivity

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Participants With Multiple Myeloma4Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        6
      title
      Conversion from MRD-negativity to MRD-positivity
    2. measurements
      1. group Id
        OG000
        value
        4
      title
      Persistent MRD-positivity
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
groups
  1. description
    Participants with MM with very good partial response (VGPR) or better after induction therapy with/without consolidative HDT/ASCT and MRD positive by bone marrow flow cytometry and MM participants who were previously MRD negative after induction and consolidation and recently (within last 3 months) turned MRD positive by bone marrow flow cytometry will be enrolled.
    id
    OG000
    title
    Participants With Multiple Myeloma
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
6 months
title
Number of Participants With MRD Negativity by the Completion of 6 Months of Daratumumab Therapy
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice